Physician profile
Scott Michael Goldstein
NPI 1174532527
$3,236.80
in general payments reported to CMS, 2019-2025
25 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $54.99 · 2021: $29.80 · 2022: $717 · 2023: $1,172 · 2024: $526 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $442.56 | 2022-2025 | Clareon, Clareon Panoptix Pro, Precision 1 |
| Merz North America, INC. | $367.94 | 2022 | |
| Sun Pharmaceutical Industries INC. | $346.14 | 2022-2025 | Cequa |
| Horizon Therapeutics Plc | $306.27 | 2020-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $273.41 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $176.31 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $155.84 | 2024-2025 | Tepezza |
| Allergan, INC. | $144.04 | 2019-2022 | |
| Abbvie INC. | $124.18 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $122.76 | 2023-2025 | Acthar |
| Revance Therapeutics, INC. | $120.39 | 2024 | Daxxify |
| Harrow Eye, LLC | $88.02 | 2024-2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $85.42 | 2023-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $77.64 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $77.00 | 2023 | Dextenza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $58.66 | 2024-2025 | Purified Cortrophin Gel |
| Organogenesis INC. | $53.12 | 2024-2025 | Novachor, Affinity |
| Dompe US, INC. | $52.43 | 2022-2024 | Oxervate |
| Rayner Intraocular Lenses Limited | $31.44 | 2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Kala Pharmaceuticals, INC. | $29.80 | 2021 | |
| Conmed Corporation | $28.29 | 2025 | Visiclear |
| Alexion Pharmaceuticals, INC. | $24.66 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Shire North American Group INC | $16.96 | 2019 | |
| Thea Pharma INC. | $16.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.